- Nikon CeLL innovation Co., Ltd. (NCLi) has signed a strategic licensing agreement with US-based RoosterBio, Inc. to provide end-to-end support for MSC and EV therapeutic development in Japan.
- The partnership integrates RoosterBio’s stem cell technology with NCLi’s CDMO manufacturing expertise, including successful 2D and 3D technology transfer.
Nikon CeLL innovation Co., Ltd. (NCLi), a subsidiary of Nikon Corporation, has entered into a strategic licensing agreement with RoosterBio, Inc., a US-based stem cell technology company. The agreement aims to provide Japan’s biopharma sector with a comprehensive solution for the development and manufacturing of human mesenchymal stem cell (MSC) and extracellular vesicle (EV) therapeutics.
The collaboration allows drug developers in Japan to access RoosterBio’s established technology platform via NCLi, and move directly into clinical manufacturing at NCLi’s Tokyo-based GCTP/GMP-compliant facility. The facility supports both 2D flask and 3D bioreactor-based manufacturing, enabling large-scale production of MSC and EV-based therapies.
Both companies have successfully completed technology transfer activities involving MSC and EV production at clinically relevant scales. These capabilities include cell expansion, harvest, formulation, cryopreservation, EV purification, and drug product manufacturing.
“We are very pleased to announce this strategic license agreement with RoosterBio, marking a significant milestone in broadening NCLi’s capabilities as a CDMO,” said Toshiyuki Nakayama, President of NCLi.
Stay ahead of trends and best practices
